Role of hylan G-F 20 in treatment of XXXX .

@entity1 @entity571 @entity134 @entity158 @entity570
OBJECTIVE: To study the efficacy of hylan G-F 20 in the treatment of @entity571 ( @entity571 ) of the hip joint. DESIGN: Prospective within-group study. SETTING: Musculoskeletal rehabilitation clinic. @entity1 : Twenty-two @entity1 (25 hips) with hip joint @entity571 who had failed to find @entity158 relief from conservative methods such as physical therapy, exercises, and @entity134 injections. Demographics included 14 @entity1 and 11 @entity1 (mean age, 56.4y), 21 of whom had mild to moderate @entity571 and 4 of whom had severe @entity571 of the hips. INTERVENTION: Each hip joint was injected with 2mL of hylan G-F 20 at 2, 3, and 4 weeks and fluoroscopic lavage with 100mL of normal saline at week 1. All @entity1 had standard hip exercise regimen after the injection. MAIN OUTCOME MEASURES: American Academy of Orthopaedic Surgeons (AAOS) Lower Limb Core Scale score and visual numeric @entity158 score. RESULTS: At 1-year follow-up, the AAOS Lower Limb Core Scale score improved from a preinjection mean of 44.2 to a follow-up mean of 86.1 (P<.05). The mean visual numeric @entity158 score improved from a preinjection mean of 8.7 (range, 6.4-10) to a follow-up mean of 2.3 (range, 0-7.2). The overall success rate was 84%. In @entity1 with mild to moderate @entity571 , the mean @entity158 score decreased from a preinjection value of 7.8 to a follow-up value of 1.7. The success rate was 90.5% in that subgroup. In @entity1 with severe @entity571 , the mean @entity158 score decreased from a preinjection value of 9.1 to a follow-up value of 3.8. The success rate was 50% in that subgroup. There were no complications related to the injection. CONCLUSION: Use of hylan G-F 20 injection is a viable option for treatment of mild to moderate @entity570 .
